NCT05827146View on ClinicalTrials.gov

Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 7, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

February 1, 2024

Conditions
Chronic Hepatitis D Infection
Interventions
DRUG

Hepalatide

Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.

DRUG

Hepalatide Placebo

Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.

Trial Locations (3)

Unknown

The first affiliated hospital of Xinjiang Medical University, Ürümqi

The first hospital of Jilin University, Changchun

the National cancer center of Mongolia, Ulaanbaatar

All Listed Sponsors
lead

Shanghai HEP Pharmaceutical Co., Ltd.

INDUSTRY

NCT05827146 - Study of Hepalatide in Chronic Hepatitis D(CHD) Patients | Biotech Hunter | Biotech Hunter